| This week's sponsor is Premier Research. | | | Discovering the Great Potential of Immuno-Oncology Drugs
Immuno-modulating agents have been around a long time, but for limited uses. New immuno-oncology pathways promise big advances against a wider range of cancers. Register now for our May 23 webinar. Premier Research. It's what we do. Best. |
Featured Story | Friday, May 5, 2017 Seattle Genetics has terminated a major drug tie-up with Immunomedics after intense legal battles, as Immunomedics revealed that it has axed its president and CEO Cynthia Sullivan. |
|
|
| This week's sponsor is Sensors Expo & Conference 2017. | | | |
Top Stories | Friday, May 5, 2017 Ovid Therapeutics has hit the bottom of the range in its IPO, resulting in it grossing $75 million. The listing gives Jeremy Levin’s Ovid enough money to take two treatments for rare neurological disorders through clinical trials and adds to the burst of biotech IPO activity. |
|
|
| Friday, May 5, 2017 Regulus Therapeutics has axed 30% of its workforce to conserve cash for its stuttering pipeline. And CEO Paul Grint, M.D., is one of those heading to the exit, having decided to hand in his notice and pass responsibility for turning the business around to COO Jay Hagan. |
|
|
| Friday, May 5, 2017 Less than a year ago, Zafgen was poleaxed by the failure of its lead weight loss drug beloranib, shedding staff as its share price tumbled. Now, the Boston biotech is back with the first data on a follow-up it hopes will put it back on track. |
|
|
| Friday, May 5, 2017 Researchers have created a $65 test designed to show which prostate cancer patients will respond to Pfizer’s Xtandi and Johnson & Johnson’s Zytiga. Retrospective analysis of plasma DNA using the droplet digital PCR assay suggest the drugs are less effective in patients with multiple copies of the androgen receptor gene. |
|
|
| Thursday, May 4, 2017 In this week's EuroBiotech Report, Bristol-Myers drops a cancer buyout option, Poxel posts diabetes data, ImCheck snags €20 million and more. |
|
|
| Friday, May 5, 2017 Takeda got FDA approval for Ariad-developed Alunbrig in NSCLC, WuXi NextCODE secured a $75 million Series B to advance precision medicine initiatives, and the FDA cited the third Dr. Reddy's plant this year. |
|
|
| Thursday, May 4, 2017 Merck & Co.'s head of translational medicine Robert Plenge will lead Celgene's immunology R&D, Sarepta CEO Edward Kaye will step down, Genentech’s pediatric oncology head Raphaël Rousseau left for startup Gritstone Oncology, plus more hirings, firings and retirings throughout the industry. |
|
|
| This week's sponsor is J.P. Morgan Private Bank. | | | How Pre-Transaction Planning Can Maximize Your Wealth
You've worked hard to build a successful healthcare business. To reap the rewards of a sale, merger, recap or IPO, be sure you maximize the value of your equity interests with careful pre-transaction planning. Learn how J.P. Morgan Private Bank can help you protect your wealth. Read the article. |
| | | VC Polaris has launched Polaris Partners VIII, a $435 million fund for technology and healthcare entrepreneurs. Polaris blog The Bill & Melinda Gates Foundation may offer up to $20 million in grant funding and equity investment for mAbs targeting gram-negative bacteria. Release IBM says its researchers have used big data analytics to see how the Ebola virus can spread from animals into the human population. Statement | |
|
Resources Presented By: Covance The ICH GCP E6 guideline has been revised to address the complexities associated with today’s clinical trials, and this concise white paper will help you understand the recent guideline changes. Learn how use of risk-based monitoring can help you comply with the guidelines and achieve efficiency in clinical trial design, implementation and reporting. Sponsored By: Veeva To thrive in a fiercely competitive market, life sciences companies need to set themselves apart by designing and executing the best trial and successfully deliver drugs to market first. Learn how a modern EDC can help. Sponsored By Reprints Desk Puzzled by Scientific Literature Access? Here is your guide for navigating knowledge management’s twists and turns! If yours is a small- or medium-sized biopharma business, we can help you putting the pieces together. Learn the secrets of top knowledge management experts who will show you how to search, discover, acquire and manage knowledge in new ways. Presented By: Covance The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of biomarkers, companion diagnostics (CDx) and complementary diagnostics. Read the white paper. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. 2017 BIO International Convention: The Largest Global Biotech Partnering Event of the Year June 19-22 | San Diego, CA Chief Medical Officer Summit in Emerging Biotechs 5th Annual May 10-11, 2017 | Boston, MA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA Medical Sensors Design Conference May 8-9, 2017 │ Boston Marriott Newton │ Newton, MA 8th Transparency and Aggregate Spend West May 23-24, 2017 | San Diego, CA MIXiii-BIOMED 2017 May 23-25, 2017 | Tel Aviv, Israel FierceBiotech Executive Breakfast- Tackling the Drug Price Problem: A Town Hall Debate June 21, 2017 | San Diego, CA Rational Combinations 360° in Immuno-Oncology June 28-29, 2017 | New York, NY |
